From the CEO

The oversubscribed issue in May showed support for Kancera’s new operational plan and resulted in a capital contribution of approximately SEK 60 million. Thus, we can now put the new plan into action which will influence both laboratory studies and the preparations for clinical trials. The goal is to take at least one of Kancera’s projects into clinical trials for cancer or cancer pain in the next 18-24 months. In parallel, we intend to validate a broader use of the drug candidates from the Fractalkine and ROR projects to demonstrate the projects’ full commercial potential and accelerate the HDAC6 and PFKFB3 projects towards selection of candidate drug.
During the summer, we have seen progress especially in the Fractalkine project where we are now well on the way to build the plan for the initial clinical study and compile the documentation required for an application for a clinical trial. In the HDAC6 project, studies show that Kancera now has developed highly potent and selective compounds that are efficiently taken up in the body following per-oral administration. Thus, the project takes steps towards the selection of a candidate drug according to plan.
In order to strengthen Kancera’s administrative structure Kancera Förvaltning AB (KFAB) has been formed. KFAB is a wholly owned subsidiary of Kancera AB, whose operations is focused mainly on the management of financial instruments, including for example, warrants. In connection with the formation of KFAB, Kancera chose to switch to the IFRS accounting system for groups which also facilitates a possible future listing on NASDAQ's other marketplaces.
Thomas Olin 
CEO Kancera AB

On May 9, Kancera received approval for clinical trial of our small molecule drug candidate KAND567, a selective blocker of the Fractalkine receptor, which can be given orally. As a result, the company has achieved the main objective of the new issue 2016, that is, to take at least one of Kancera's products into clinical trials. The planned clinical trial, which will be conducted in the Netherlands, aims at mapping the safety, tolerability and pharmaco-kinetics of KAND567 in healthy subjects.

Interesting clinical results using an injected antibody to Fraktalkine were recently announced by the pharmaceutical company Eisai. The results show that blocking of the Fractalkine system produces the desired effects in humans against treatment-recacitrant forms of autoimmune disease, which is in line with what we have been able to demonstrate with KAND567.

The advantage of KAND567 over an antibody is that it is easier to administer and reaches sick organs or tumors easier. Overall, this supports us in our belief that Kancera's KAND567 can achieve clinical and commercial success in the treatment of treatment-recacitrant diseases.

During the period, the acquisition of the Fractalkine project from Acturum Real Estate AB was also completed. Payment for the Fractalkine project is made through a three-stage offset issue with a total of 6 million shares in Kancera AB. In connection with the application for a clinical trial, the first payment of 2 million shares has been made.

The development of the KAND567 has recently been highlighted by specialist journals such as "SCRIP Magazine" and "Drug Discovery Today". Their interest is based on the fact that KAND567 leads the development of a new class of small molecules that have the potential to change the treatment of autoimmune diseases, inflammation and cancer. For an animation that shows how KAND567 can work against cancer and autoimmune diseases, see this video on YouTube: https://youtu.be/ZiW0fQ73W00 .

 A new generation of ROR inhibitors has been developed that can be dosed in a manner that maintains an attack on cancer cells in the body throughout the day. This has been demonstrated in the laboratory to be essential in order to get resistant solid tumor cells to destroy themselves.  

In the HDAC6 project, Kancera continues to reach the targets set for the Vinnova-supported studies.

In the PFKFB3 project, new EU funding has resulted in additional research power being added to the development of PFKFB3 inhibitors. Kanceras PFKFB3 inhibitors have recently been shown to interact effectively in cell studies with a rapidly growing class of drugs (PARP inhibitors) against ovarian and breast cancer. This opens the possibility of increasing the effect of PARP inhibitors on several forms of treatment-resistant cancer.

 All in all this means that Kancera is taking steps towards identifying the next drug candidate to be prepared for clinical trials. In order to enable a continued high rate of product development against cancer and autoimmune diseases in 2018, Kancera is now strengthening its working capital through a preferential issue.

We will do our utmost to reach our ambitious goals.

Thomas Olin,
CEO
Kancera AB (publ)

 

May 2017


Thomas Olin, CEO

Copyright 2010 KANCERA AB, KAROLINSKA INSTITUTET SCIENCE PARK, BANVAKTSVÄGEN 22, 171 48 SOLNA. TEL: +46 (0)850 12 60 80 Website policy